Researcher.Life Logo

Arthritis Research and Therapy : Impact Factor & More

eISSN: 1478-6362pISSN: 1478-6354
JournalOpen Access

Key Metrics

CiteScore
7.6
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
SJR
Q2Immunology
SNIP
1.56
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Arthritis Research and Therapy

Arthritis Research and Therapy Journal Specifications

Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2790 | USD 3290 | GBP 2390
Publication Time14
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2003
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 14
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Arthritis Research and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Arthritis Research and Therapy

Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies.
  • 19 May 2026
  • Arthritis research & therapy
Lipid metabolism dysregulation in rheumatoid arthritis: from multi-omics discovery to adjunctive therapy with conjugated linoleic acid.
  • 19 May 2026
  • Arthritis research & therapy
Targeting mitochondrial fission-autophagy axis in rheumatoid arthritis: leflunomide promote apoptosis of fibroblast-like synoviocytes.
  • 16 May 2026
  • Arthritis research & therapy
Aberrant sphingosine-1-phosphate receptor 1 expression on activated naive B cells associated with disease activity and lupus nephritis in systemic lupus erythematosus.
  • 14 May 2026
  • Arthritis research & therapy
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.
  • 11 May 2026
  • Arthritis research & therapy
IRE1/p‑JNK/NRF2 axis-mediated GPX4 upregulation underlies ferroptosis resistance in rheumatoid arthritis fibroblast-like synoviocytes.
  • 9 May 2026
  • Arthritis research & therapy
Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies.
  • 19 May 2026
  • Arthritis research & therapy
Lipid metabolism dysregulation in rheumatoid arthritis: from multi-omics discovery to adjunctive therapy with conjugated linoleic acid.
  • 19 May 2026
  • Arthritis research & therapy
Targeting mitochondrial fission-autophagy axis in rheumatoid arthritis: leflunomide promote apoptosis of fibroblast-like synoviocytes.
  • 16 May 2026
  • Arthritis research & therapy
Aberrant sphingosine-1-phosphate receptor 1 expression on activated naive B cells associated with disease activity and lupus nephritis in systemic lupus erythematosus.
  • 14 May 2026
  • Arthritis research & therapy
Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.
  • 11 May 2026
  • Arthritis research & therapy
IRE1/p‑JNK/NRF2 axis-mediated GPX4 upregulation underlies ferroptosis resistance in rheumatoid arthritis fibroblast-like synoviocytes.
  • 9 May 2026
  • Arthritis research & therapy

FAQs on Arthritis Research and Therapy